FerGene Employee Directory
Biotechnology ResearchMassachusetts, United States0-1 Employees
FerGene is a privately held biotechnology company based in Cambridge, Massachusetts, formed through a partnership between Ferring Pharmaceuticals and Blackstone Life Sciences. The small company focuses on developing gene therapy approaches for bladder cancer, with a particular emphasis on non-muscle invasive bladder cancer (NMIBC) and the needs of urologists and patients affected by the disease. Its lead program, nadofaragene firadenovec (rAd-IFN/Syn3), is being prepared for U.S. commercialization for high-grade, BCG-unresponsive NMIBC, following its launch in November 2019. Early clinical progress is indicated by the presentation of Phase 3 data for nadofaragene firadenovec at the Society of Urologic Oncology Congress in December 2019. FerGene operates within the biotechnology research sector, aiming to offer new therapeutic options where standard care has shown limited improvement over the past two decades.